Kyowa Kirin FY26 Q1 profit rises 95% to JPY 12 billion; revenue climbs 13% to JPY 118.5 billion

  • Kyowa Kirin posted Q1 FY2026 revenue of JPY 118.5 billion, up 13% year over year, while core operating profit jumped 78% to JPY 20.0 billion.
  • Profit climbed 95% to JPY 12.0 billion, despite JPY 5.0 billion in impairment losses tied to discontinuation of rocatinlimab clinical program.
  • Full-year forecast kept revenue unchanged at JPY 520.0 billion, while core operating profit was revised up to JPY 130.0 billion from JPY 100.0 billion.
  • Full-year profit outlook held at JPY 75.0 billion, with higher core operating profit offset by estimated closing costs and other expenses related to rocatinlimab termination.
  • Management also outlined plans to reorganize research institute and consolidate Japan research sites into a new Yokohama facility to strengthen drug discovery capabilities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.